NCT06999343

Exploring the Anti-ageing Effects of Metformin in COPD

• Status: Not Yet Recruiting
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 212 (estimated)
• Sponsor: Fundación Instituto de Investigación Sanitaria de Navarra · Academic / Other
• Sex: All
• Age: 40 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

Prospective, multicentre, double-blind, placebo-controlled, randomised, prospective clinical trial comparing the effect of metformin 850 mg twice daily with placebo in COPD patients with evidence of emphysema (by CT scan or reduced DLCO) who are known to have a rapid decrease in FEV1. Main objective: To compare the change in FEV1 at 3 years follow-up in patients receiving metformin versus placebo. Participants will take metformin (850mg) or placebo twice daily for 3 years.

Conditions

• COPD

Interventions

Type	Name	Description
DRUG	Metformin 850Mg Tab	Tolerance phase dose: 850mg/24h for 2 weeks. Treatment dose: 1700 mg twice daily.
OTHER	Placebo	Tolerance phase dose: One tablet/24h for 2 weeks. Treatment dose: Two tablets twice daily.

Timeline

• Start date: 2025-09-01
• Primary completion: 2029-05-01
• Completion: 2029-09-01
• First posted: 2025-05-31
• Last updated: 2025-05-31